Kailera Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Kailera Therapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-115.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 85% of Healthcare companies in United States.
Cash Cushion Ratio
+31%Cash, after subtracting all debt, equals 31% of its market value (net cash).
Higher than 69% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (8)
Kailera Therapeutics, Inc. made a loss over the last year. Kailera Therapeutics, Inc. owes $0.08 for every $1 it owns.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKailera Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.49The share price is 1.49 times Kailera Therapeutics, Inc.'s book value per share, lower than 67% of Healthcare companies in United States.
Market cap
$1.7 BThe total market value of all of Kailera Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 71% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.1 BWhat Kailera Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$8.63Net worth divided by the number of shares. The share price of $12.85 is 1.5 times this, which is the P/B above.
Owes vs Owns
0.08×Kailera Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 91% of Healthcare companies in United States.
Dividend yield
NoneKailera Therapeutics, Inc. does not currently pay a dividend.
Cash vs debt
Net cashKailera Therapeutics, Inc. held $535 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Kailera Therapeutics, Inc.: $1.7 B ÷ $1.1 B (30 Jun 2026) = 1.5.
How much does Kailera Therapeutics, Inc. owe compared with what it owns?
Kailera Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 91% of Healthcare companies in United States.
Does Kailera Therapeutics, Inc. pay a dividend?
No. Kailera Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.